Document Detail


Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non-ST-Segment-Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease: Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.
MedLine Citation:
PMID:  24736878     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The use of bivalirudin versus unfractionated heparin monotherapy in patients without ST-segment-elevation myocardial infarction is not well defined.
METHODS AND RESULTS: The study population consisted of patients enrolled in the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry with either non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease, who underwent percutaneous coronary intervention with either unfractionated heparin or bivalirudin monotherapy. Propensity score matching was used to adjust for baseline characteristics. The primary bleeding (in-hospital composite bleeding-access site bleeding, thrombolysis in myocardial infarction major/minor bleeding, or transfusion) and primary (in-hospital death/myocardial infarction) and secondary ischemic outcomes (death/myocardial infarction/unplanned repeat revascularization at 12 months) were evaluated. Propensity score matching yielded 1036 patients with non-ST-segment-elevation acute coronary syndromes and 2062 patients with stable ischemic heart disease. For the non-ST-segment-elevation acute coronary syndrome cohort, bivalirudin use was associated with lower bleeding (difference, -3.3% [-0.8% to -5.8%]; P=0.01; number need to treat=30) without increase in either primary (difference, 1.2% [4.1% to -1.8%]; P=0.45) or secondary ischemic outcomes, including stent thrombosis (difference, 0.0% [1.3% to -1.3%]; P=1.00). Similarly, in the stable ischemic heart disease cohort, bivalirudin use was associated with lower bleeding (difference, -1.8% [-0.4% to -3.3%]; P=0.01; number need to treat=53) without increase in either primary (difference, 0.4% [2.3% to -1.5%]; P=0.70) or secondary ischemic outcomes, including stent thrombosis (difference, 0.0% [0.7% to -0.7%]; P=1.00) when compared with unfractionated heparin monotherapy.
CONCLUSIONS: Among patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease undergoing percutaneous coronary intervention, bivalirudin use during percutaneous coronary intervention when compared with unfractionated heparin monotherapy was associated with lower bleeding without significant increase in ischemic outcomes or stent thrombosis.
Authors:
Sripal Bangalore; Michael J Pencina; Neal S Kleiman; David J Cohen
Related Documents :
15065258 - Epr oximetry in the beating heart: myocardial oxygen consumption rate as an index of po...
8347798 - Coronary hemodynamics during isometric handgrip and atrial pacing in patients with angi...
2721548 - Cardiac and hemodynamic effects of the selective bradycardic agent kc 8857 during exerc...
1574978 - Myocardial circulatory and metabolic effects of halothane when used to control intraope...
12381078 - Modification of treatment strategies over a period of 14 years has markedly reduced car...
15273438 - Reliability of a semi-automated technique of cerebral infarct volume measurement with ct.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-4-15
Journal Detail:
Title:  Circulation. Cardiovascular interventions     Volume:  -     ISSN:  1941-7632     ISO Abbreviation:  Circ Cardiovasc Interv     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-4-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101499602     Medline TA:  Circ Cardiovasc Interv     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The green tea extract epigallocatechin-3-gallate inhibits irradiation-induced pulmonary fibrosis in ...
Next Document:  In Vivo and In Vitro Immunomodulatory Potential of Swertiamarin Isolated from Enicostema axillare (L...